表紙
市場調查報告書

人工水晶體 (IOL):開發平台分析,白內障的疾病負擔、流行病學的預測,資本交易趨勢

Intraocular Lenses (IOLs): Pipeline Analytics, Cataract Burden, Cataract Epidemiology & Epidemiology Forecast and Deals Activity from 2010 to 2019

出版商 GervanoRA Data Services LLP 商品編碼 813724
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
人工水晶體 (IOL):開發平台分析,白內障的疾病負擔、流行病學的預測,資本交易趨勢 Intraocular Lenses (IOLs): Pipeline Analytics, Cataract Burden, Cataract Epidemiology & Epidemiology Forecast and Deals Activity from 2010 to 2019
出版日期: 2019年03月22日內容資訊: 英文 55 Pages
簡介

本報告提供全球人工水晶體 (IOL) 市場上臨床實驗趨勢相關分析,相關疾病 (白內障)的概要和發病情形 (流行病學的預測),近幾年主要的資本交易趨勢,主要的推動及阻礙市場要素,目前臨床實驗的發展情形 (各階段)等資訊彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

  • 分析概要
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第3章 疾病概要

  • 白內障的概要與病因
  • 白內障的診斷方法
  • 白內障的治療方法
  • 白內障的疾病負擔 (美國/世界)
  • 概率論的流行病學預測 (手法、前提條件):世界/美國

第4章 市場動態/資本交易活動

  • 企業收購
  • 事業合作
  • 授權合約
  • 事業聯盟、企業聯合
  • 基本/補充的PMA (零件製造認證)的核准
  • 新的國際核准

第5章 開發平台分析

  • 開發平台分析:各開發階段
    • 臨床實驗平台
    • 前臨床開發平台
    • 早期R&D (藥物研發) 開發平台
  • 開發平台分析:各地區
  • 開發平台分析:設備的各類型
  • 開發平台分析:各症狀
  • 開發平台分析:各大學、研究機關
目錄
Product Code: GERMD216

‘Intraocular Lenses (IOLs): Pipeline Analytics, Cataract Burden, Cataract Epidemiology & Epidemiology Forecast and Deals Activity from 2010 to 2019’ report analyzed and assessed in detail the analytics on Intraocular Lens competitive space by covering pipeline IOLs by stage of development, equipment type, geography, Cataract disease burden (Global Cataract Burden & US Cataract Burden) and Cataract epidemiology and epidemiology forecast (2025).

Report has even provided analytics on deals activity of IOL space by covering deal types like acquisitions, mergers, partnering, collaborations, alliances and agreements from 2010 to till the date.

This report is focused to provide snapshot of drivers, restraints and opportunities in intraocular lens competitive space. All pipeline IOLs are provided with detailed descriptions and technological specifications.

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1 REPORT DESCRIPTION
  • 1.2 METHODOLOGY
  • 1.3 ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1 REPORT MAJOR FINDINGS
  • 2.2 DRIVERS
  • 2.3 RESTRAINTS
  • 2.4 OPPORTUNITIES

3. DISEASE OVERVIEW

  • 3.1. CATARACT OVERVIEW & PATHOGENESIS
  • 3.2 CATARACT DIAGNOSIS
  • 3.3 CATARACT TREATMENT
  • 3.4 CATARACT BURDEN
    • 3.4.1 US CATARACT BURDEN
    • 3.4.2 GLOBAL CATARACT BURDEN
  • 3.5. PROBABILISTIC EPIDEMIOLOGY FORECAST (Method & Assumptions)
    • 3.5.1. PROBABILISTIC GLOBAL CATARACT EPIDEMIOLOGY FORECAST
    • 3.5.2. PROBABILISTIC US CATARCT EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS/DEALS ACTIVITY

  • 4.1. ACQUISITION DEALS
  • 4.2 COLLABORATION DEALS
  • 4.3 LICENSING AGREEMENT DEALS
  • 4.4 PARTNERING AND ALLIANCES DEALS
  • 4.5. ORIGINAL & SUPPLEMENTAL PMA APPROVALS
  • 4.6 NEW INTERNATIONAL APPROVALS

5. PIPELINE ANALYSIS

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. CLINICAL PIPELINE IOLs
    • 5.1.2. PRECLINICAL PIPELINE IOLs
    • 5.1.3. EARLY R&D PIPELINE IOLs
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
  • 5.3. PIPELINE ANALYSIS BY EQUIPMENT TYPE
  • 5.4. PIPELINE ANALYSIS BY INDICATION
  • 5.5. PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES

LIST OF TABLES

  • TABLE 01: GLOBAL CATARACT EPIDEMIOLOGY (2018) AND FORECAST (2019-2025)
  • TABLE 02: US CATARACT EPIDEMIOLOGY (2018) AND FORECAST (2019-2025)
  • TABLE 03: TOTAL KEY DEALS ACTIVITY IN INTRAOCULAR LENSES (IOLS) COMPETITIVE SPACE
  • TABLE 04: MAJOR ACQUISITION DEALS ACTIVITY IN INTRAOCULAR LENSES COMPETITIVE SPACE
  • TABLE 05: MAJOR COLLABORATION DEALS ACTIVITY IN INTRAOCULAR LENSES COMPETITIVE SPACE
  • TABLE 06: MAJOR LICENSING DEALS ACTIVITY IN INTRAOCULAR LENSES COMPETITIVE SPACE
  • TABLE 07: MAJOR PARTNERING & ALLIANCE DEALS ACTIVITY IN IOLS COMPETITIVE SPACE
  • TABLE 08: KEY INTERNATIONAL REGULATORY APPROVALS FOR IOLS
  • TABLE 09: SUMMARY OF PIPELINE IOLS BY STAGE OF DEVELOPMENT
  • TABLE 10: CLINICAL STAGE PIPELINE IOLS
  • TABLE 11: PRECLINICAL STAGE PIPELINE IOLS
  • TABLE 12: EARLY R&D STAGE PIPELINE IOLS
  • TABLE 13: UNITED STATES PIPELINE IOLS VS STAGE OF DEVELOPMENT
  • TABLE 14: EUROPE PIPELINE IOLS VS HIGHEST STAGE OF DEVELOPMENT (HSD)
  • TABLE 15: ACCOMMODATING IOLS VS HIGHEST STAGE OF DEVELOPMENT (HSD)
  • TABLE 16: TORIC IOLS VS HIGHEST STAGE OF DEVELOPMENT (HSD)
  • TABLE 17: PMMA & OTHER IOLS VS HIGHEST STAGE OF DEVELOPMENT (HSD)
  • TABLE 18: PIPELINE IOLS VS INDICATIONS
  • TABLE 19: PIPELINE IOLS INDICATED FOR CATARACT
  • TABLE 20: PIPELINE IOLS INDICATED FOR PRESBYOPIA
  • TABLE 21: PIPELINE IOLS INDICATED FOR ANIRIDIA
  • TABLE 22: PIPELINE IOLS INDICATED FOR MYOPIA

LIST OF FIGURES

  • FIGURE 01: GLOBAL CATARACT EPIDEMIOLOGY FORECAST (2019-2025)
  • FIGURE 02: GLOBAL CATARACT EPIDEMIOLOGY COMPARE 2018 VS 2025(POPULATION IN MILLIONS)
  • FIGURE 03: US CATARACT EPIDEMIOLOGY FORECAST (2019-2025)
  • FIGURE 04: US CATARACT EPIDEMIOLOGY COMPARE 2018 VS 2025(POPULATION IN MILLIONS)
  • FIGURE 05: DEALS (MERGERS & ACQUISITIONS) ACTIVITY IN IOLS COMPETITIVE SPACE
  • FIGURE 06: ORIGINAL PMA & SUPPLEMENTAL PMA APPROVALS SINCE 1985
  • FIGURE 07: PIPELINE IOLS BY GEOGRAPHY